The convergence of clinical and biomarker effects in a biomarker enriched subgroup in the Phase II ALS dataset with AP-101 is ...
Add Yahoo as a preferred source to see more of our stories on Google. AL-S Pharma's lead ALS asset AL-S Pharma is planning a registrational study for its amyotrophic lateral sclerosis (ALS) monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results